Work

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Year: 2017

Type: article

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.1365.1365

Authors: Michael P. Rettig, John E. Godwin, Norbert Vey, Bernard A. Fox, Carmen Ballesteros‐Merino, Carlo Bifulco, Daner Li, Daniel Primo, Joan Ballesteros, Jichao Sun, Hélène Lelièvre, Jan Baughman, Ross La Motte‐Mohs, John Muth, Paul A. Moore, Ezio Bonvini, Jon M. Wigginton, John F. DiPersio, Jan K. Davidson-Moncada

Institutions: Washington University in St. Louis, Providence Portland Medical Center, Institut Paoli-Calmettes, MacroGenics (United States), Centre de Recherche en Cancérologie de Marseille

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2991428077

FWCI: 2.322

Cites:

Cited by: 12

Related to: 10